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an average LOS of only 4.62 days. The total cost per hospital-
ization was also lowest for HCV at $11,797 and was signiﬁcantly
higher for HIV ($14,595, P < 0.0001). The total cost per hospi-
talization for HIV and HCV co-infections was $14,686. The
total cost of non-HCV or HIV hospitalizations was nearly half
($8,859). The probability of death associated with HCV, HIV,
and co-infected HCV and HIV was 3.5%, 5.1% and 5.6%
respectively while the probability of death associated with non-
HIV or HIV-related hospitalizations was only 2.1%. CONCLU-
SIONS: This is one of few studies to quantify differences in
inpatient costs and outcomes associated with HCV, HIV, and
HCV and HIV co-infection in a multi-payer US population.
Hospitalizations related to HCV and HIV co-infections were
longer and more expensive compared to those related to HCV
only. Policy and other decision makers should be aware of this
burden as strategies to allocate resources are developed.
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OBJECTIVES: Central venous catheter (CVC) is the main reason
for intrahospitalary bacteraemia. The prevalence of nosocomial
Catheter-related bacteraemia (CRB) hospitalwide is 6.58%.
Gram-positive microorganisms are responsible for more than
50% of these bacteraemia. This study aimed to clear manage-
ment of non-permanent CRB caused by Gram-positives and
resource use associated. METHODS: A multicenter, observa-
tional, transversal cost study was carried out, where every proven
CRB was recorded. CRB was deﬁned as a positive culture from
the distal end of the catheter plus at least a positive peripheral
blood culture involving isolations of the same micro-organism-.
The study was performed from the hospital perspective; therefore
only medical direct costs (€2007) were included: hospitalization
cost, diagnosis test cost, and analytical cost. Costs were obtained
from Spanish databases. Qualitative and quantitative descriptive
analyses were made for all the variables. RESULTS: A total of 23
proven CRB and more than 400 suspected catheter infections,
which did not meet criteria inclusion, were identiﬁcated, in 5
Spanish hospitals. Average age was 60.17 (SD 13,799) years old,
being 52.2% women. Coagulase-negative Staphylococcus was
the micro-organism responsible for the 73.9% of CRB, mostly
S. epidermidis (56.5%). S. aureus was isolated in 17.4% cases.
Vancomycin was the most frequently prescribed antibiotic
(47.8%), followed by teicoplanin (26.1%), with a mean duration
of 8.48 (SD 4481) days. Nevertheless, 52% patients required
new antibiotics as cloxaciline (20%), vancomycin (20%) and
teicoplanin (20%), due to treatment failure, with a mean extra-
hospital treatment duration of 5.7 (SD 4547) days. Mean time
to CRB resolution-time since initial clinical signs until fever
clearance- was 6.65 (SD 4.608) days, with a mean cost per
episode of €4375.42. The 95% of costs are attributable to length
of hospitalization, with a mean cost per episode of €4150.81,
therefore, being the driver cost. CONCLUSIONS: CRB is asso-
ciated with a profound increase in resource use. Prevention, early
diagnosis, and intervention for non-permanent catheter related
bacteraemia might result in cost savings for the National Health
System.
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OBJECTIVES: Previous economic analyses of gram + cSSTIs
have not included costs related to outpatient parenteral antibiotic
therapy (OPAT). The objective of this analysis was to develop a
core model framework and appropriate inputs to estimate
medical and drug costs within both inpatient and outpatient
components of care for treating gram + cSSTIs and serve as a
basis for comparing vancomycin with newer antibiotics.
METHODS: A 4-week decision model was developed to estimate
the direct total, inpatient, and outpatient costs of treating
gram + cSSTIs from a payer perspective taking into account suc-
cesses, failures, and adverse events. Published literature provided
clinical inputs and resource use data, with validation by expert
opinion. Cost data was derived from literature and standard CPT
coding reimbursements. Sensitivity analyses tested efﬁcacy, com-
plication rates, length of stay, and other resource use parameters.
Costs were reported in 2008US$. RESULTS: Drug acquisition
cost for 14 days of vancomycin 1gm IV q12hr was $257;
however, the total 4-week cost of treatment including clinical
failures, complications, and OPAT ranged from $8,214–$13,133
(66–86% of cost inpatient, 14–33% outpatient). Important
vancomycin cost drivers beyond the inpatient stay ($1219/day)
included OPAT cost ($175/day), line placement and complica-
tions related to OPAT ($739/patient), physician visits ($192/
patient), injection supply/admin costs ($183/patient), and lab
work ($98/patient). Antibiotics with favorable dosing/admin-
istration proﬁles reduced OPAT costs and provided opportunity
for early discharge. The most sensitive model variables for total
cost were the MRSA efﬁcacy rate, length of hospital stay, days of
OPAT and line complications. CONCLUSIONS: The model
framework and results suggest that the costs associated with
generic vancomycin for treatment of cSSTIs may be substantial,
with a signiﬁcant portion of costs extending into the outpatient
arena. The budget impact of newer antimicrobials should be
evaluated in the context of total medical cost offsets from both
inpatient and outpatient perspectives.
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OBJECTIVES: To understand real-world impacts of venous leg
ulcer (VLU) on direct medical costs and productivity in the US
and the UK. METHODS: This prospective, observational, multi-
center study enrolled 112 patients with VLU (US: 76 and UK:
36). Patients were followed for 12 weeks or until all their ulcers
healed in 2007 and 2008. Data were gathered on health care
resources used at the study site as well as outside the study site
(using patient diaries). Standard national data sources were used
to assign unit costs to the resources used. The mean direct
medical cost was estimated from the US payer, US provider, and
UK National Health Service (NHS) perspectives separately and
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